Upstream Biosciences Inc. (OTC BB: UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has announced today the provisional patent filing of prostate cancer biomarkers that could be useful for determining patients with a genetic risk of developing prostate cancer.
